2025 Q3 -tulosraportti
81 päivää sitten
‧36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
3 040
Myynti
Määrä
280
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | NON | NRD | ||
| 70 | NON | NRD | ||
| 275 | NON | NRD | ||
| 10 | NON | NRD | ||
| 15 | NON | NRD |
Ylin
17,5VWAP
Alin
16,8VaihtoMäärä
1,6 90 564
VWAP
Ylin
17,5Alin
16,8VaihtoMäärä
1,6 90 564
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenIt must be positive for Curasight. Does anyone know what it could mean for the case? Faster and cheaper to get to market? Here's ChatGPT's answer: Here is the concrete, investor-relevant meaning of FDA’s new “one pivotal trial”-standard for Curasight: ⸻ 🧬 What Curasight does (briefly) • uTRACE: diagnostics (PET-tracer that shows uPAR expression in tumor) • uTREAT: targeted radionuclide therapy against the same target The strategy is theranostics: first find the patients (uTRACE), then treat them (uTREAT). ⸻ 🎯 What the change means – broken down 1) uTRACE (diagnostics) → clearly positive With FDA’s new standard, Curasight can increasingly aim for: 👉 One strong pivotal study + supplementary evidence instead of two Consequences: • 🕒 Shorter path to market in USA • 💰 Lower development costs • 🤝 Better partnering position (Big Pharma loves shorter, cheaper development processes) What FDA will look at in one study: • Sensitivity/specificity vs. standard imaging • Correlation between uPAR signal and clinical decision (does it change treatment?) • Reproducibility across centers ➡️ If they get it right, uTRACE could potentially reach registration basis with one main study. ⸻ 2) uTREAT (therapy) → positive, but not a “free pass” For treatments, FDA is still more cautious. The new policy means: • It can be approved on one pivotal study • but only if the effect is clear and clinically meaningful (e.g. PFS/OS or strong surrogates) Consequences for Curasight: • Still likely a larger, robust study • FDA may require: • more safety data • longer follow-up • possibly supplementary evidence ➡️ So: time saving possible, but not as significant as for uTRACE ⸻ 📊 Capital & risk – what you really care about 💰 Capital needs The new FDA line can: • reduce the need for two phase 3 studies • save many millions euro • reduce dilution 📉 Risk • One study = greater binary risk • If it fails → no fallback-trial 📈 Valuation The market usually reacts positively to: • shorter path to approval • lower capex • greater likelihood of M&A/partnership ⸻ 🇪🇺 EU angle (relevant for you) Although European Medicines Agency does not automatically copy FDA: • Studies are often designed globally (FDA + EMA in one setup) • If FDA accepts one study, EMA can sometimes: • accept the same dataset • or require an extra European cohort/extension ➡️ The net: global development becomes easier ⸻ 🧾 Bottom line for Curasight Bull case: • uTRACE approved on one pivotal study • faster partner agreement • uTREAT can follow with strong data Base case: • uTRACE: one study + extra supporting data • uTREAT: still one large study, but with high requirements Risk case: • One study fails → greater setback (because there is no “study #2” in reserve) ⸻ 👉 In short For Curasight, the change means: Faster, cheaper and more partner-friendly path to market – especially for uTRACE – but still with high requirements for uTREAT
·1 päivä sittenIt's so tempting to buy more when it's going so well. I'm quite satisfied with 125% return, and I only regret that I didn't buy more. Hmmmm, should I, shouldn't I? 👀
·2 päivää sittenUpcoming events and results: TD Cowen's 46th Annual Health Care Conference Tuesday, March 3, 2026, 11:50 AM ET (5:50 PM CET) Boston, MA, USA Corporate presentation focusing on pipeline progress, including ongoing Phase 1 trial with uTREAT® in glioblastoma. Management holds 1:1 meetings with investors and partners. Live audio webcast is expected to be available. SNMMI Annual Meeting (Society of Nuclear Medicine and Molecular Imaging) May 30 – June 2, 2026 Los Angeles Convention Center, Los Angeles, CA, USA Participation/attendance. Focus on nuclear medicine and theranostics; potential poster presentations of data from trials. Expected pipeline results and milestones: uTREAT® – Glioblastoma (Phase 1, dosimetry and safety) 1. Preliminary data (January 2026): Encouraging – clear uptake in the tumor, dosimetry in line with expectations, no safety issues; several patients enrolled (announced January 12, 2026). 2. Top-line data: Q2 2026 (safety, full dosimetry and early efficacy). 3. Transition to next phase: Planned expansion to Phase 1/2a and basket trial (up to 5 indications, including GBM and prostate cancer) in 2026 after Phase 1 completion. uTRACE® – Prostate cancer (Phase 2, part 2 in recruitment) 1. Recruitment: All European sites active; expected completion first half of 2026. 2. Top-line results: H1 2026 (efficacy in diagnostics before prostatectomy). Basket trial (uTREAT®/uTRACE®) 1. Multiple indications (up to 5, incl. GBM, prostate cancer, etc.) – Planned Phase 2 start expected in 2026 after GBM Phase 1.·1 päivä sitten · MuokattuAgreed Martin. The Curasight share has really shown strength lately and remained stable around 15 kr. We have also exceeded 4,100 owners on Nordnet, and the number is continuously increasing, which indicates increased interest 😊 Most have probably familiarized themselves with the case and hopefully know this is just the beginning of it all. After 10 years of research, it's starting to bear fruit 🙏🏼
·3 päivää sittenSo March 3rd we'll know more.. or should they present data before they present them,
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
81 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIt must be positive for Curasight. Does anyone know what it could mean for the case? Faster and cheaper to get to market? Here's ChatGPT's answer: Here is the concrete, investor-relevant meaning of FDA’s new “one pivotal trial”-standard for Curasight: ⸻ 🧬 What Curasight does (briefly) • uTRACE: diagnostics (PET-tracer that shows uPAR expression in tumor) • uTREAT: targeted radionuclide therapy against the same target The strategy is theranostics: first find the patients (uTRACE), then treat them (uTREAT). ⸻ 🎯 What the change means – broken down 1) uTRACE (diagnostics) → clearly positive With FDA’s new standard, Curasight can increasingly aim for: 👉 One strong pivotal study + supplementary evidence instead of two Consequences: • 🕒 Shorter path to market in USA • 💰 Lower development costs • 🤝 Better partnering position (Big Pharma loves shorter, cheaper development processes) What FDA will look at in one study: • Sensitivity/specificity vs. standard imaging • Correlation between uPAR signal and clinical decision (does it change treatment?) • Reproducibility across centers ➡️ If they get it right, uTRACE could potentially reach registration basis with one main study. ⸻ 2) uTREAT (therapy) → positive, but not a “free pass” For treatments, FDA is still more cautious. The new policy means: • It can be approved on one pivotal study • but only if the effect is clear and clinically meaningful (e.g. PFS/OS or strong surrogates) Consequences for Curasight: • Still likely a larger, robust study • FDA may require: • more safety data • longer follow-up • possibly supplementary evidence ➡️ So: time saving possible, but not as significant as for uTRACE ⸻ 📊 Capital & risk – what you really care about 💰 Capital needs The new FDA line can: • reduce the need for two phase 3 studies • save many millions euro • reduce dilution 📉 Risk • One study = greater binary risk • If it fails → no fallback-trial 📈 Valuation The market usually reacts positively to: • shorter path to approval • lower capex • greater likelihood of M&A/partnership ⸻ 🇪🇺 EU angle (relevant for you) Although European Medicines Agency does not automatically copy FDA: • Studies are often designed globally (FDA + EMA in one setup) • If FDA accepts one study, EMA can sometimes: • accept the same dataset • or require an extra European cohort/extension ➡️ The net: global development becomes easier ⸻ 🧾 Bottom line for Curasight Bull case: • uTRACE approved on one pivotal study • faster partner agreement • uTREAT can follow with strong data Base case: • uTRACE: one study + extra supporting data • uTREAT: still one large study, but with high requirements Risk case: • One study fails → greater setback (because there is no “study #2” in reserve) ⸻ 👉 In short For Curasight, the change means: Faster, cheaper and more partner-friendly path to market – especially for uTRACE – but still with high requirements for uTREAT
- ·1 päivä sittenIt's so tempting to buy more when it's going so well. I'm quite satisfied with 125% return, and I only regret that I didn't buy more. Hmmmm, should I, shouldn't I? 👀
- ·2 päivää sittenUpcoming events and results: TD Cowen's 46th Annual Health Care Conference Tuesday, March 3, 2026, 11:50 AM ET (5:50 PM CET) Boston, MA, USA Corporate presentation focusing on pipeline progress, including ongoing Phase 1 trial with uTREAT® in glioblastoma. Management holds 1:1 meetings with investors and partners. Live audio webcast is expected to be available. SNMMI Annual Meeting (Society of Nuclear Medicine and Molecular Imaging) May 30 – June 2, 2026 Los Angeles Convention Center, Los Angeles, CA, USA Participation/attendance. Focus on nuclear medicine and theranostics; potential poster presentations of data from trials. Expected pipeline results and milestones: uTREAT® – Glioblastoma (Phase 1, dosimetry and safety) 1. Preliminary data (January 2026): Encouraging – clear uptake in the tumor, dosimetry in line with expectations, no safety issues; several patients enrolled (announced January 12, 2026). 2. Top-line data: Q2 2026 (safety, full dosimetry and early efficacy). 3. Transition to next phase: Planned expansion to Phase 1/2a and basket trial (up to 5 indications, including GBM and prostate cancer) in 2026 after Phase 1 completion. uTRACE® – Prostate cancer (Phase 2, part 2 in recruitment) 1. Recruitment: All European sites active; expected completion first half of 2026. 2. Top-line results: H1 2026 (efficacy in diagnostics before prostatectomy). Basket trial (uTREAT®/uTRACE®) 1. Multiple indications (up to 5, incl. GBM, prostate cancer, etc.) – Planned Phase 2 start expected in 2026 after GBM Phase 1.·1 päivä sitten · MuokattuAgreed Martin. The Curasight share has really shown strength lately and remained stable around 15 kr. We have also exceeded 4,100 owners on Nordnet, and the number is continuously increasing, which indicates increased interest 😊 Most have probably familiarized themselves with the case and hopefully know this is just the beginning of it all. After 10 years of research, it's starting to bear fruit 🙏🏼
- ·3 päivää sittenSo March 3rd we'll know more.. or should they present data before they present them,
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
3 040
Myynti
Määrä
280
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | NON | NRD | ||
| 70 | NON | NRD | ||
| 275 | NON | NRD | ||
| 10 | NON | NRD | ||
| 15 | NON | NRD |
Ylin
17,5VWAP
Alin
16,8VaihtoMäärä
1,6 90 564
VWAP
Ylin
17,5Alin
16,8VaihtoMäärä
1,6 90 564
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
2025 Q3 -tulosraportti
81 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIt must be positive for Curasight. Does anyone know what it could mean for the case? Faster and cheaper to get to market? Here's ChatGPT's answer: Here is the concrete, investor-relevant meaning of FDA’s new “one pivotal trial”-standard for Curasight: ⸻ 🧬 What Curasight does (briefly) • uTRACE: diagnostics (PET-tracer that shows uPAR expression in tumor) • uTREAT: targeted radionuclide therapy against the same target The strategy is theranostics: first find the patients (uTRACE), then treat them (uTREAT). ⸻ 🎯 What the change means – broken down 1) uTRACE (diagnostics) → clearly positive With FDA’s new standard, Curasight can increasingly aim for: 👉 One strong pivotal study + supplementary evidence instead of two Consequences: • 🕒 Shorter path to market in USA • 💰 Lower development costs • 🤝 Better partnering position (Big Pharma loves shorter, cheaper development processes) What FDA will look at in one study: • Sensitivity/specificity vs. standard imaging • Correlation between uPAR signal and clinical decision (does it change treatment?) • Reproducibility across centers ➡️ If they get it right, uTRACE could potentially reach registration basis with one main study. ⸻ 2) uTREAT (therapy) → positive, but not a “free pass” For treatments, FDA is still more cautious. The new policy means: • It can be approved on one pivotal study • but only if the effect is clear and clinically meaningful (e.g. PFS/OS or strong surrogates) Consequences for Curasight: • Still likely a larger, robust study • FDA may require: • more safety data • longer follow-up • possibly supplementary evidence ➡️ So: time saving possible, but not as significant as for uTRACE ⸻ 📊 Capital & risk – what you really care about 💰 Capital needs The new FDA line can: • reduce the need for two phase 3 studies • save many millions euro • reduce dilution 📉 Risk • One study = greater binary risk • If it fails → no fallback-trial 📈 Valuation The market usually reacts positively to: • shorter path to approval • lower capex • greater likelihood of M&A/partnership ⸻ 🇪🇺 EU angle (relevant for you) Although European Medicines Agency does not automatically copy FDA: • Studies are often designed globally (FDA + EMA in one setup) • If FDA accepts one study, EMA can sometimes: • accept the same dataset • or require an extra European cohort/extension ➡️ The net: global development becomes easier ⸻ 🧾 Bottom line for Curasight Bull case: • uTRACE approved on one pivotal study • faster partner agreement • uTREAT can follow with strong data Base case: • uTRACE: one study + extra supporting data • uTREAT: still one large study, but with high requirements Risk case: • One study fails → greater setback (because there is no “study #2” in reserve) ⸻ 👉 In short For Curasight, the change means: Faster, cheaper and more partner-friendly path to market – especially for uTRACE – but still with high requirements for uTREAT
- ·1 päivä sittenIt's so tempting to buy more when it's going so well. I'm quite satisfied with 125% return, and I only regret that I didn't buy more. Hmmmm, should I, shouldn't I? 👀
- ·2 päivää sittenUpcoming events and results: TD Cowen's 46th Annual Health Care Conference Tuesday, March 3, 2026, 11:50 AM ET (5:50 PM CET) Boston, MA, USA Corporate presentation focusing on pipeline progress, including ongoing Phase 1 trial with uTREAT® in glioblastoma. Management holds 1:1 meetings with investors and partners. Live audio webcast is expected to be available. SNMMI Annual Meeting (Society of Nuclear Medicine and Molecular Imaging) May 30 – June 2, 2026 Los Angeles Convention Center, Los Angeles, CA, USA Participation/attendance. Focus on nuclear medicine and theranostics; potential poster presentations of data from trials. Expected pipeline results and milestones: uTREAT® – Glioblastoma (Phase 1, dosimetry and safety) 1. Preliminary data (January 2026): Encouraging – clear uptake in the tumor, dosimetry in line with expectations, no safety issues; several patients enrolled (announced January 12, 2026). 2. Top-line data: Q2 2026 (safety, full dosimetry and early efficacy). 3. Transition to next phase: Planned expansion to Phase 1/2a and basket trial (up to 5 indications, including GBM and prostate cancer) in 2026 after Phase 1 completion. uTRACE® – Prostate cancer (Phase 2, part 2 in recruitment) 1. Recruitment: All European sites active; expected completion first half of 2026. 2. Top-line results: H1 2026 (efficacy in diagnostics before prostatectomy). Basket trial (uTREAT®/uTRACE®) 1. Multiple indications (up to 5, incl. GBM, prostate cancer, etc.) – Planned Phase 2 start expected in 2026 after GBM Phase 1.·1 päivä sitten · MuokattuAgreed Martin. The Curasight share has really shown strength lately and remained stable around 15 kr. We have also exceeded 4,100 owners on Nordnet, and the number is continuously increasing, which indicates increased interest 😊 Most have probably familiarized themselves with the case and hopefully know this is just the beginning of it all. After 10 years of research, it's starting to bear fruit 🙏🏼
- ·3 päivää sittenSo March 3rd we'll know more.. or should they present data before they present them,
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
3 040
Myynti
Määrä
280
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | NON | NRD | ||
| 70 | NON | NRD | ||
| 275 | NON | NRD | ||
| 10 | NON | NRD | ||
| 15 | NON | NRD |
Ylin
17,5VWAP
Alin
16,8VaihtoMäärä
1,6 90 564
VWAP
Ylin
17,5Alin
16,8VaihtoMäärä
1,6 90 564
Välittäjätilasto
Dataa ei löytynyt